Corxel to advance oral obesity drug to Phase III trials

Corxel's Oral GLP-1RA CX11 Achieves Positive Phase II Results

Corxel Pharmaceuticals announced positive Phase II results for its oral GLP-1RA candidate, CX11, in the US, paving the way for global pivotal Phase III studies. The trial (NCT07011797) enrolled 246 obese or overweight adults, demonstrating up to 11.5% weight loss over 36 weeks with a consistent trajectory and a favorable gastrointestinal tolerability and safety profile. These US findings align with competitive data from a Phase III program conducted in China by partner Vincentage Pharma, reinforcing confidence in CX11 as a potential effective and tolerable oral option for weight management.

• Robust Phase II Efficacy and Safety Profile: Corxel's CX11 achieved significant weight reduction of up to 11.5% in obese and overweight American patients during the 36-week Phase II trial. The drug maintained a consistent weight loss trajectory without slowing and exhibited a favorable gastrointestinal tolerability and safety profile across various dosing regimens, supporting its potential as a well-tolerated oral treatment.
• Global Development Strategy Confirmed: The positive US Phase II results for CX11 are consistent with data from a previously completed Phase III program in China, conducted with regional partner Vincentage Pharma. This dual validation reinforces Corxel's confidence in the drug's competitive profile, leading to the company's decision to advance CX11 into pivotal global Phase III studies for weight management.
• Positioning in a Growing Oral Obesity Market: CX11 is entering a rapidly expanding oral GLP-1RA market, projected to reach $34.3 billion by 2031 with a 48.4% CAGR. The market already features launched oral drugs like Novo Nordisk's Wegovy and Eli Lilly's Foundayo, alongside other late-stage candidates from companies such as AstraZeneca and Structure Therapeutics, highlighting the competitive yet high-potential landscape for Corxel's oral therapy.

CX11's Promising Phase II Efficacy and Tolerability in Obesity

The SURMOUNT-1 trial evaluated tirzepatide (weekly injectable at 5, 10, and 15 mg doses) across 9 RCTs encompassing 7,111 participants, with follow-up to 72 weeks. At medium-term follow-up (12–18 months), tirzepatide demonstrated a mean body weight reduction of −16.03% (95% CI −18.91 to −13.14; moderate-certainty evidence) and a 3.60-fold increase in the proportion achieving ≥5% weight loss versus placebo. Long-term data (3.5 years, 1,032 participants) showed sustained reductions of −15.66% (95% CI −19.14 to −12.18; moderate-certainty evidence). The SURMOUNT-MAINTAIN trial, a Phase 3b, 112-week placebo-controlled study in 378 randomized adults (mean BMI 40.1 kg/m²), reported −21.9% bodyweight change with tirzepatide at maximum tolerated dose versus −9.9% with placebo (p<0.0001), with gastrointestinal events constituting the most common adverse effects, predominantly mild-to-moderate and occurring mainly during dose escalation. Complementary network meta-analysis data from 25 trials further confirmed tirzepatide 15 mg as delivering the greatest percent weight reduction among pharmacological agents (MD −17.97%), with CagriSema closely following (MD −17.84%), and both achieving marked superiority at the ≥20% weight-loss threshold.

The OASIS 1 trial examined oral semaglutide 50 mg daily over 68 weeks in adults without type 2 diabetes with obesity (BMI ≥30 kg/m²) or overweight with ≥1 obesity-related complication. In a comparative analysis, tirzepatide 10 mg and 15 mg were associated with statistically significantly greater reductions in body weight (mean differences of −4.48% [95% CI −6.35 to −2.61] and −5.59% [95% CI −7.52 to −3.77], respectively) and waist circumference relative to oral semaglutide, with cardiometabolic safety profiles broadly comparable between agents. A separate Cochrane systematic review of 18 RCTs (27,949 participants) synthesizing semaglutide data demonstrated high-certainty evidence of a −10.73% mean body weight reduction at medium-term follow-up (MD −10.73%, 95% CI −12.24 to −9.21), with a 2.68-fold increase in the proportion achieving ≥5% weight loss. Serious adverse events were very uncertain in effect (RR 1.01; very low-certainty evidence), while non-serious adverse events showed a modest increase (RR 1.11; low-certainty evidence), and adverse events leading to withdrawal were elevated long-term (RR 2.03; moderate-certainty evidence). The VISTA trial evaluated elecoglipron, an oral small-molecule GLP-1 receptor agonist, across doses of 5–75 mg once daily over 36 weeks in 310 adults without type 2 diabetes. Mean bodyweight change ranged from −2.6% (5 mg) to −10.5% (75 mg with weekly titration) versus −0.6% with placebo, with 40.4–88.8% of participants achieving ≥5% weight loss compared with 15.6% on placebo. Nausea, constipation, diarrhoea, and vomiting were the most commonly reported adverse events across elecoglipron doses.

A meta-analysis of five RCTs evaluating mazdutide — a dual GLP-1 and glucagon receptor agonist — in non-diabetic adults with obesity demonstrated significant reductions in percentage body weight (MD −12.42%, 95% CI −16.15 to −8.68%), absolute body weight (MD −9.76 kg), waist circumference (MD −7.98 cm), systolic blood pressure (MD −7.68 mmHg), total cholesterol (MD −0.57 mmol/L), and LDL cholesterol (MD −0.37 mmol/L), with adverse events only modestly increased (RR 1.12), primarily mild-to-moderate in severity. In the paediatric setting, a Cochrane review of 37 RCTs (4,218 participants) evaluating pharmacological interventions including GLP-1 receptor agonists, metformin, orlistat, and topiramate-containing regimens found that pharmacotherapy reduced BMI by 1.80 kg/m² (95% CI −2.36 to −1.24; low-certainty evidence) and body weight by 5.47 kg (95% CI −7.45 to −3.50; low-certainty evidence) versus placebo, with little-to-no difference in overall adverse event risk (RR 1.03; moderate-certainty evidence) and no clinically meaningful impact on quality of life. Notably, only 8 of 37 studies enrolled children below adolescent age, and data were rarely disaggregated by age group, underscoring the need for adequately powered, longer-duration trials with outcomes extending beyond anthropometric endpoints.

Unpacking the Design of Corxel's CX11 Phase II Trial

The Phase II landscape for obesity and overweight trials spans a range of intervention modalities, with endpoint selection increasingly reflecting both metabolic and functional dimensions of disease burden. Across the most relevant trials, study designs range from randomized controlled trials evaluating pharmacological agents to device-based and surgical interventions, with endpoints anchored to quantifiable weight and cardiometabolic outcomes.